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variability. In contrast, a single embryonic stem cell (ESC) line can
be repetitively cryopreserved, thawed, expanded, and differentiated
into various cellular components serving as a renewable and well-
characterized stem cell source. We, therefore, determined whether
ESCs could be used to reconstitute marrow and blood in major
histocompatibility (MHC) mismatched mice. To induce differen-
tiation toward HSC in vitro, ESCs were cultured in methylcellulose
with hematopoietic cytokines, stem cell factor (SCF), interleukin-3
(IL-3), interleukin-6 (IL-6). After 7-10 of culture, H2b ESC-
derived cytokine induced hematopoietic stem cells (c-kit/CD34)
were isolated by ﬂow cytometry and injected either intra bone
marrow (IBM) or intravenously (IV) into lethally irradiate MHC
mismatched H2d recipient mice. From two to twenty weeks after
injection, the peripheral blood demonstrated increasing donor de-
rived H2b positive mononuclear cells that included donor derived
T lymphocytes, B lymphocytes, monocytes and granulocytes with-
out clinical or histologic evidence of graft versus host disease
(GvHD). Mixed lymphocyte culture (MLC) proliferation assays
demonstrated T cell tolerance to both recipient and donor but
intact 3rd party proliferative responses and interferon-
 produc-
tion. Embryonic stem cells may be used as a renewable alternate
marrow donor source that reconstitutes hematopoiesis with intact
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CD8 cytotoxic T lymphocytes (CTLs) are endowed with a
powerful capacity to induce speciﬁc tolerance against their histo-
compatibility antigens (veto). Very recently, we developed a new
approach to deplete CTLs of host-reactive clones by stimulating
the donor T cells against 3rd party stimulators in the absence of
exogenous IL-2. It could be anticipated that this procedure, which
leads to a marked frequency reduction of anti-host clones, should
also be associated with substantial narrowing of the TCR reper-
toire, thereby limiting the use of these veto cells for tolerance
induction. In the present study we used a new technique (TcLand-
scape) which enables qualitative and quantitative analysis of V	
chain usage at the CDR3 length distribution level to compare the
repertoire of anti-3rd party CTLs to that of the original donor.
Mouse and human anti-3rd party CTLs were prepared as previ-
ously described. Mouse splenocytes of Balb/c and FVB were used
as effectors and stimulators, respectively. Human PBMC from
normal donors were stimulated against EBV transformed cell lines,
completely mismatched for HLA class1. cDNA samples obtained
from mouse and human CD8 responder T cells before (day 0)
and after initiation of culture (days 22 and 33 respectively) were
analyzed for V	 repertoire. The analysis showed that in CTLs of
both human and mice, a signiﬁcant ampliﬁcation or reduction was
evident only in particular CDR3 lengths of speciﬁc V	 families.
Thus, mouse anti-3rd party CTLs exhibit marked clonal reductions
in V	3, V	5, V	12, V	13 and V	16. Changes in the latter one
were most dramatic and it is almost oligoclonal. In contrast, only
minor alterations were found in all the other V	 families indicating
a preservation of broad repertoire. Analysis of CDR3 lengths of
anti-3rd party human CTLs showed similar preservation of broad
repertoire along with marked reduction of particular CDR3 length
clones in V	12, V	15 and V	21. These ﬁndings are of particular
relevance to BMT, as it might enable to use anti-3rd party CTLs
not only for enhancement of engraftment, but also for adoptive
transfer of immunity during the early post transplant period. Fur-
thermore, these results raise new possibilities for molecular prob-
ing of the antigens which trigger alloreactivity in mouse and in
man.
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ADOPTIVE TRANSFER OF EX VIVO COSTIMULATED AUTOLOGOUS T-
CELLS AFTER AUTOTRANSPLANTATION FOR MYELOMA (MM)ACCELER-
ATES POST-TRANSPLANT T-CELL RECOVERY
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Ex-vivo co-stimulation of autologous T-cells using anti-CD3/
anti-CD28-conjugated magnetic beads may restore T-cell respon-
siveness toward MM cells. 40 patients (pts) received ex-vivo co-
stimulated autologous T-cells after autotransplantation. The mean
age was 58 (range 43-72), 72% were male, 24% had IgA parapro-
teins, 12% had del 13 or complex karyotypes and the median 	2m
level at diagnosis was 3.32 mg/L (range 1.09-73.7). Lymphocyte
collections were followed by cyclophosphamide (4.5 g/m2) G-CSF
for stem cell mobilization melphalan (200 mg/m2 or 140 mg/m2 for
pts 70). T-cells were cultured for 12 days with anti-CD3/anti-
CD28-immobilized immunomagnetic beads & IL-2 supplementa-
tion (100 units/ml). During a run-in phase, 12 pts received T-cells
post-transplant (day 12) alone; afterwards, 28 pts participated
in a 2  2 randomization in which they received T-cells “early”
(day 12) or “late” (day 100) after transplant also received 2
immunizations with the pneumococcal conjugate vaccine (PCV,
Prevnar®) days 30 90 or 3 immunizations (prior to T-cell
collection, days 30, 90) to test immune responses. 27 pts re-
ceived 1 or more PCV immunizations and there were no grade 3/4
adverse events. Anti-pneumococcal antibody T-cell response assays
are underway for pts who completed the study. 33 pts received a
mean of 8.11  109 costimulated T-cells (range 1.6-11) all infu-
sions were well tolerated. There were no delayed adverse effects
except for grade 1-2 facial/upper body rashes in 6 pts (median 13
days after T-cells) and 1 episode of grade 2 conjunctivitis. At T-cell
harvesting, the mean % of CD3  cells in culture was 94.2% the
mean T-cell doubling level was 5.2. Among the randomized pts, at
day  42 post-transplant (30 days after T-cell infusion for the
“early” groups), the mean CD4/CD3 count was 679/l (95% CI,
347-1012) for the “early” T-cell recipients vs 278/l (95% CI,
59-497) for the “late” T-cell recipients (T-cells not yet infused)
[P  0.03]. The mean CD8/CD3 counts were 1826/l (95% CI,
1275-2376) 1105/l (95% CI, 404-1806) for the “early” and “late”
T-cell recipient respectively at day 42 [P  0.07]. 32 pts were
evaluable for clinical responses (8 are too early). There were 6 CRs,
15 VGPRs (90% reduction in paraprotein levels), 10 PRs (50-
90% reductions), 1 pt had no response. Post-transplant infusions of
ex-vivo expanded autologous T-cells are feasible and well-tolerated
may be associated with accelerated T-cell recovery.
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ACCELERATED IMMUNE RECONSTITUTION USING LLME TREATED DO-
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Delayed immune reconstitution is a major cause of morbidity and
mortality after T-cell depleted allogeneic progenitor cell transplant
(PCT). To accelerate immune reconstitution without GVHD, we
have administered escalating doses of L-leucyl-L-leucine methyl
ester (LLME) treated lymphocytes (DLI) to 9 patients post
CD34 cell-enriched PCT in an ongoing phase I trial. LLME’s
cellular toxicity occurs after its polymerization by dipeptidyl pep-
tidase, leading to selective depletion of cells with cytotoxic effector
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